 |
| https://www.orphan-star.com/ |
You mean to tell me that Little Shkreli is running a big ole pharmaceutical company all by himself from prison?
I do not believe it.
He has help.
To begin, he is just a funding keyman because he knows people who want to launder money.
You heard me.
This is an orphan drug program, where they test the drugs on tiny humans in far away lands, in exchange for food, funded through USAID, or other sophisticated financial fraud schemes.
Orphan drugs is an exclusive set of drugs for those 1 in 1,000,000 childhood diseases.
Whenever I see an orphan drug program, I immediately think of epigenetic human subject research testing, more intuitively recognized as using children of "The Poors" as lab rats, Drugging children.
 |
| http://druggingchildren.blogspot.com/ |
Martin Shkreli still running his drug company from prison, report says
Martin Shkreli, the disgraced pharmaceutical executive who is prison for securities fraud, still carries influence at his former drug company, now called Phoenixus AG, and may emerge from prison richer than ever, according to a Wall Street Journal report.
Shkreli and his company Turing Pharmaceuticals AG came under fire in 2015 for inflating the prices of rare drugs, including toxoplasmosis drug Daraprim, which had its price tag raised by more than 5,000 percent overnight.
In 2018, Shkreli was sentenced to prison for seven years, not for price gouging, but on conspiracy and securities-fraud charges.
Now 16 months into the sentence and equipped with a contraband cell phone, Shkreli is still running his company from behind bars, reported The Wall Street Journal.
A few weeks ago, he even called the company’s chief executive and tried to fire him, the report said, citing a person familiar with the exchange. Later, Shkreli agreed to suspend the CEO instead.
That activity could land Shkreli in trouble, the Journal reports, adding that the Federal Bureau of Investigation has interviewed associates about his role at Phoenixus.
However, Shkreli, who is 35, may find it a risk worth taking as he may even leave prison richer than when he went in, according to the Journal.
Phoenixus, in which he holds a 40 percent share, could be worth $3.7 billion by the time he is due to be freed in 2023, the report said. Plus, despite being in jail, he has been researching to acquire more rare drugs in various stages of development.
The newspaper reports that Shkreli has worked to consolidate control of the company and advised on two offers in 2018 to buy shares from existing shareholders at a steep discount.
=
He also recently managed deals for Phoenixus, including a $20 million research deal with Orphan Star Therapeutics LLC to work on drug candidates for several rare diseases, and a licensing deal with Seelos Therapeutics, the Journal said.
Some of Phoenixus’ shareholders told the newspaper they were concerned about Shkreli’s influence on the company and are pushing for more transparency and a possible sale of the company. Others say they fear Shkreli may attempt to seize control of the company through complicated financial transactions.
Meanwhile, Shkreli owes the federal government at least $7.6 million and may be forced to sell some of his stake in Phoenixus.
Akeel Mithani, a Phoenixus board member, said told the Journal in an email that Shkreli “gets treated like any other shareholder” and that his cellphone use is known but limited to “business related communication” via his lawyers.
Voting is beautiful, be beautiful ~ vote.©
No comments:
Post a Comment